Last $54.20 USD
Change Today -0.18 / -0.33%
Volume 36.6K
STE On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 10:55 AM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).

steris corp (STE) Snapshot

Open
$54.66
Previous Close
$54.38
Day High
$54.66
Day Low
$54.02
52 Week High
05/12/14 - $55.36
52 Week Low
02/5/14 - $39.90
Market Cap
3.2B
Average Volume 10 Days
252.0K
EPS TTM
$2.49
Shares Outstanding
59.1M
EX-Date
06/3/14
P/E TM
21.8x
Dividend
$0.84
Dividend Yield
1.54%
Current Stock Chart for STERIS CORP (STE)

steris corp (STE) Related Bloomberg News

View More Bloomberg News

steris corp (STE) Related Businessweek News

No Related Businessweek News Found

steris corp (STE) Details

STERIS Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company’s Healthcare segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers; liquid chemical sterilant processing systems; washer/disinfector systems; general and specialty surgical tables; surgical and examination lights; equipment management systems; operating room storage cabinets; warming cabinets; scrub sinks; gastrointestinal endoscopy accessories; connectivity solutions, such as operating room integration, workflow, patient tracking, and instrument management; cleaning chemistries and sterility assurance products; and cleansing products, including hard surface disinfectants, and skin care and hand hygiene solutions. This segment also provides maintenance programs and repair services; sterilization and surgical management consulting services; information management and decision support services; and other support services comprising construction and facility planning, engineering support, device testing, customer education, hand hygiene process excellence, asset management/planning, and the sale of replacement parts. Its Life Sciences segment offers formulated cleaning chemistries, vaporized hydrogen peroxide generators; sterilizers; and high-purity water equipment, as well as various preventive maintenance programs and repair services. The company’s STERIS Isomedix Services segment provides contract processing services using gamma irradiation and ethylene oxide technologies; and microbial reduction services. It sells its products to end users, dealers, and distributors. The company was formerly known as Innovative Medical Technologies and changed its name to STERIS Corporation in 1987. STERIS Corporation was founded in 1985 and is headquartered in Mentor, Ohio.

6,000 Employees
Last Reported Date: 05/29/14
Founded in 1985

steris corp (STE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $788.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $351.8K
Senior Vice President and Group President of ...
Total Annual Compensation: $401.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $321.3K
Senior Vice President of Infection Prevention...
Total Annual Compensation: $312.6K
Compensation as of Fiscal Year 2014.

steris corp (STE) Key Developments

Steris Corp. Declares Quarterly Dividend, Payable on June 26, 2014

Steris Corp. announced that its Board of Directors has authorized a quarterly dividend of $0.21 per common share. The dividend is payable on June 26, 2014 to shareholders of record at the close of business on June 5, 2014.

Steris Corporation Announces Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014; Provides Earnings Guidance for Fiscal 2015

STERIS Corporation announced financial results for the fourth quarter and full year ended March 31, 2014. As reported, fiscal 2014 fourth quarter revenue was $465.3 million compared with $428.2 million in the fourth quarter of fiscal 2013. Operating income for the fourth quarter was $59.6 million compared with $65.1 million in the fourth quarter of fiscal 2013. Net income was $38.9 million, or $0.65 per diluted share, compared with net income of $41.4 million, or $0.70 per diluted share in the fourth quarter of fiscal 2013. On an adjusted basis, fiscal 2014 fourth quarter revenue increased 9% to $465.3 million compared with adjusted revenue of $426.2 million in the fourth quarter of fiscal 2013, driven by double digit growth in Healthcare and high single digit growth in Isomedix. Adjusted operating income for the fourth quarter increased 32% to $86.5 million, compared with adjusted operating income for the fourth quarter of fiscal 2013 of $65.4 million. Adjusted net income for the fourth quarter of fiscal 2014 increased 30% to $54.2 million, or $0.91 per diluted share, compared with adjusted net income for the previous year of $41.5 million, or $0.70 per diluted share. The improvement in profit was driven by the increase in volume and operating expense leverage. As reported, fiscal 2014 full year revenue increased 8% to $1.62 billion compared with $1.50 billion in fiscal 2013. On an adjusted basis, revenue increased 10% in fiscal 2014. As reported, fiscal 2014 operating income was $206.8 million compared with $242.8 million in fiscal 2013. Adjusted operating income increased 14% to $250.1 million in fiscal 2014 compared with $219.7 million in fiscal 2013. As reported, fiscal 2014 net income was $129.4 million or $2.17 per diluted share, compared with net income of $160.0 million or $2.72 per diluted share in fiscal 2013. Adjusted net income for fiscal 2014 increased 7% to $147.9 million or $2.48 per diluted share compared with $137.8 million or $2.34 per diluted share in fiscal 2013. Net cash provided by operations for fiscal 2014 was $209.6 million, compared with $227.8 million in fiscal 2013. Free cash flow for fiscal 2014 was $128.0 million compared with $140.4 million in the prior year. The decline in free cash flow is primarily due to payments for the Company's annual incentive compensation program which did not occur in fiscal 2013, as well as the impact of strong working capital improvements in the prior year. Based upon current trends, the company expects revenue growth in the range of 15-17% in fiscal 2015 when compared with fiscal 2014. Adjusted earnings per diluted share are anticipated to be in the range of $2.78 to $2.91 for the full fiscal year. Healthcare segment revenue is expected to grow in the range of 21-23%. Life Sciences segment revenue is expected to grow mid-single digits. Isomedix segment revenue growth is expected to be in the mid-single digits. The adjusted effective tax rate is anticipated to be approximately 35%. Fiscal 2015 free cash flow is anticipated to be approximately $135 million. Capital expenditures are anticipated to be approximately $95 million, reflecting the impact of acquisitions, continued expansion within Isomedix, new product development and general maintenance and repair for existing facilities.

Steris Seeks Acquisitions

Steris Corp. (NYSE:STE) seeks acquisitions. "I was speaking specifically about acquisitions in the specialty service space. And that is, we felt that we needed a certain capabilities to be able to have a good -- very good spot to provide great value to our customers. And we feel that we've gathered that set of capabilities now. So it's not to say that we wouldn't do opportunistic acquisitions in that space if they came up; we would. But in terms of feeling like we needed to do some other significant component to have a good package, we don't really feel that way. So I was really directing my comments there. Now we do have some significant integration work to be done, obviously, but it's largely in that specialty service space. Eschmann is a relatively small business; it will fit nicely into our capital business in healthcare. So I don't see that being a large integration problem. The real integration is occurring in the specialty services space. So we would feel that we have capacity to do other acquisitions outside of that space. I think we're going to let those guys sort that work out. They got a lot of work to do, and we will let them sort that out. The next little bit, we will be looking predominately in other areas," said Walt Rosebrough, Steris, President & Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STE:US $54.20 USD -0.18

STE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chemed Corp $97.42 USD +0.22
Sirona Dental Systems Inc $82.49 USD +0.14
Teleflex Inc $107.22 USD +0.25
West Pharmaceutical Services Inc $42.22 USD -0.20
View Industry Companies
 

Industry Analysis

STE

Industry Average

Valuation STE Industry Range
Price/Earnings 25.1x
Price/Sales 2.0x
Price/Book 3.1x
Price/Cash Flow 24.9x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STERIS CORP, please visit www.steris.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.